431 related articles for article (PubMed ID: 34803493)
1. Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer.
Yang H; Deng Q; Ni T; Liu Y; Lu L; Dai H; Wang H; Yang W
Int J Biol Sci; 2021; 17(15):4207-4222. PubMed ID: 34803493
[No Abstract] [Full Text] [Related]
2. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
[TBL] [Abstract][Full Text] [Related]
3. Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice.
Yu Y; Shi X; Zheng Q; Wang X; Liu X; Tan M; Lv G; Zhang P; Martin RC; Li Y
Int J Biol Sci; 2021; 17(10):2576-2589. PubMed ID: 34326695
[No Abstract] [Full Text] [Related]
4. E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment.
González-Romero F; Mestre D; Aurrekoetxea I; O'Rourke CJ; Andersen JB; Woodhoo A; Tamayo-Caro M; Varela-Rey M; Palomo-Irigoyen M; Gómez-Santos B; de Urturi DS; Núñez-García M; García-Rodríguez JL; Fernández-Ares L; Buqué X; Iglesias-Ara A; Bernales I; De Juan VG; Delgado TC; Goikoetxea-Usandizaga N; Lee R; Bhanot S; Delgado I; Perugorria MJ; Errazti G; Mosteiro L; Gaztambide S; Martinez de la Piscina I; Iruzubieta P; Crespo J; Banales JM; Martínez-Chantar ML; Castaño L; Zubiaga AM; Aspichueta P
Cancer Res; 2021 Jun; 81(11):2874-2887. PubMed ID: 33771899
[TBL] [Abstract][Full Text] [Related]
5. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma.
Kutlu O; Kaleli HN; Ozer E
Can J Gastroenterol Hepatol; 2018; 2018():8543763. PubMed ID: 30228976
[TBL] [Abstract][Full Text] [Related]
6. A Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma.
Kumar DP; Santhekadur PK; Seneshaw M; Mirshahi F; Uram-Tuculescu C; Sanyal AJ
Hepatology; 2019 Apr; 69(4):1520-1534. PubMed ID: 30394550
[TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
8. Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARa axis through dual regulation of lipid metabolism and mitochondrial function.
Zhang J; Zhang W; Yang L; Zhao W; Liu Z; Wang E; Wang J
Phytomedicine; 2023 Jan; 109():154589. PubMed ID: 36610145
[TBL] [Abstract][Full Text] [Related]
9. HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia.
Povero D; Chen Y; Johnson SM; McMahon CE; Pan M; Bao H; Petterson XT; Blake E; Lauer KP; O'Brien DR; Yu Y; Graham RP; Taner T; Han X; Razidlo GL; Liu J
J Hepatol; 2023 Aug; 79(2):378-393. PubMed ID: 37061197
[TBL] [Abstract][Full Text] [Related]
10.
Li T; Lin X; Shen B; Zhang W; Liu Y; Liu H; Wang Y; Zheng L; Zhi F
Front Immunol; 2022; 13():1047570. PubMed ID: 36531991
[TBL] [Abstract][Full Text] [Related]
11. CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity.
Fujiwara N; Nakagawa H; Enooku K; Kudo Y; Hayata Y; Nakatsuka T; Tanaka Y; Tateishi R; Hikiba Y; Misumi K; Tanaka M; Hayashi A; Shibahara J; Fukayama M; Arita J; Hasegawa K; Hirschfield H; Hoshida Y; Hirata Y; Otsuka M; Tateishi K; Koike K
Gut; 2018 Aug; 67(8):1493-1504. PubMed ID: 29437870
[TBL] [Abstract][Full Text] [Related]
12. O-GlcNAc transferase promotes fatty liver-associated liver cancer through inducing palmitic acid and activating endoplasmic reticulum stress.
Xu W; Zhang X; Wu JL; Fu L; Liu K; Liu D; Chen GG; Lai PB; Wong N; Yu J
J Hepatol; 2017 Aug; 67(2):310-320. PubMed ID: 28347804
[TBL] [Abstract][Full Text] [Related]
13. Fatty Acid Binding Protein 4 (FABP4) Overexpression in Intratumoral Hepatic Stellate Cells within Hepatocellular Carcinoma with Metabolic Risk Factors.
Chiyonobu N; Shimada S; Akiyama Y; Mogushi K; Itoh M; Akahoshi K; Matsumura S; Ogawa K; Ono H; Mitsunori Y; Ban D; Kudo A; Arii S; Suganami T; Yamaoka S; Ogawa Y; Tanabe M; Tanaka S
Am J Pathol; 2018 May; 188(5):1213-1224. PubMed ID: 29454748
[TBL] [Abstract][Full Text] [Related]
14. Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients.
Enooku K; Tsutsumi T; Kondo M; Fujiwara N; Sasako T; Shibahara J; Kado A; Okushin K; Fujinaga H; Nakagomi R; Minami T; Sato M; Uchino K; Nakagawa H; Kondo Y; Asaoka Y; Tateishi R; Ueki K; Ikeda H; Yoshida H; Moriya K; Yotsuyanagi H; Kadowaki T; Koike K
J Gastroenterol; 2020 Feb; 55(2):227-243. PubMed ID: 31602526
[TBL] [Abstract][Full Text] [Related]
15. Altered fatty acid-binding protein 4 (FABP4) expression and function in human and animal models of hepatocellular carcinoma.
Thompson KJ; Austin RG; Nazari SS; Gersin KS; Iannitti DA; McKillop IH
Liver Int; 2018 Jun; 38(6):1074-1083. PubMed ID: 29171144
[TBL] [Abstract][Full Text] [Related]
16. Circadian dysfunction induces NAFLD-related human liver cancer in a mouse model.
Padilla J; Osman NM; Bissig-Choisat B; Grimm SL; Qin X; Major AM; Yang L; Lopez-Terrada D; Coarfa C; Li F; Bissig KD; Moore DD; Fu L
J Hepatol; 2024 Feb; 80(2):282-292. PubMed ID: 37890720
[TBL] [Abstract][Full Text] [Related]
17. Lack of FGF21 promotes NASH-HCC transition
Zheng Q; Martin RC; Shi X; Pandit H; Yu Y; Liu X; Guo W; Tan M; Bai O; Meng X; Li Y
Theranostics; 2020; 10(22):9923-9936. PubMed ID: 32929325
[No Abstract] [Full Text] [Related]
18. TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis.
Wang X; Zeldin S; Shi H; Zhu C; Saito Y; Corey KE; Osganian SA; Remotti HE; Verna EC; Pajvani UB; Schwabe RF; Tabas I
J Hepatol; 2022 Apr; 76(4):910-920. PubMed ID: 34902531
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
Charrez B; Qiao L; Hebbard L
World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
[TBL] [Abstract][Full Text] [Related]
20. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]